

**SYMTUZA® (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide),
PREZCOBIX® (darunavir/cobicistat), PREZISTA® (darunavir), INTELENCE®
(etravirine), and EDURANT® (rilpivirine) -
Media Statement – April 2022 – Janssen Takes Further Legal Action to Help End
the Distribution of Counterfeit HIV Medicines in the United States**

SUMMARY

- On April 26, 2022, the Janssen Pharmaceutical Companies of Johnson & Johnson issued a media statement confirming that they have taken further legal action to help end the distribution of counterfeit medicines for the treatment of human immunodeficiency virus (HIV) in the United States following an investigation that identified criminal activity involving distributors not authorized to sell Janssen medicines.
- Please click here for the link to the [Media Statement](#).¹

REFERENCE

1. Janssen Pharmaceutical Companies of Johnson & Johnson. Janssen Takes Further Legal Action to Help End the Distribution of Counterfeit HIV Medicines in the United States. 26 April 2022. Available at: https://www.janssen.com/us/sites/www_janssen_com_usa/files/janssen_takes_further_legal_action_to_help_end_the_distribution_of_counterfeit_hiv_medicines_in_the_united_states.pdf.